0001809726-24-000001.txt : 20240108 0001809726-24-000001.hdr.sgml : 20240108 20240108163115 ACCESSION NUMBER: 0001809726-24-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 EFFECTIVENESS DATE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Claris Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001809726 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-501855 FILM NUMBER: 24520526 BUSINESS ADDRESS: STREET 1: 299 PAVONIA AVENUE 3-8 CITY: JERSEY CITY STATE: NJ ZIP: 07302 BUSINESS PHONE: 201-344-7638 MAIL ADDRESS: STREET 1: 299 PAVONIA AVENUE 3-8 CITY: JERSEY CITY STATE: NJ ZIP: 07302 D 1 primary_doc.xml X0708 D LIVE 0001809726 Claris Biotherapeutics, Inc. 299 PAVONIA AVENUE 3-8 JERSEY CITY NJ NEW JERSEY 07302 201-344-7638 DELAWARE None None Corporation true Clarke Atwell c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Executive Officer Director Reza Dana c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Director Kenneth Harrison c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Director Marc de Garidel c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Director Meredith Fisher c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Director Henry Rath c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Executive Officer Susan Orr c/o Claris Biotherapeutics, Inc. 299 Pavonia Avenue 3-8 Jersey City NJ NEW JERSEY 07302 Executive Officer Biotechnology Decline to Disclose 06b false 2023-12-28 false true false 0 9999998 9999998 0 false 3 0 0 1841183 true This represents an estimate of the aggregate cash compensation payable to named executive officers and directors (e.g., base salary, consulting fees, and discretionary bonuses) during the approximate period beginning July 1, 2024 and ending June 31, 2025. false Claris Biotherapeutics, Inc. /s/ Clarke Atwell Clarke Atwell President & CEO 2024-01-05